[1]
Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol 2018; 24(29): 3204-21.
[http://dx.doi.org/10.3748/wjg.v24.i29.3204] [PMID: 30090002]
[http://dx.doi.org/10.3748/wjg.v24.i29.3204] [PMID: 30090002]
[2]
Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66(1): 6-30.
[http://dx.doi.org/10.1136/gutjnl-2016-312288] [PMID: 27707777]
[http://dx.doi.org/10.1136/gutjnl-2016-312288] [PMID: 27707777]
[3]
Roszczenko-Jasińska P, Wojty MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol 2020; 104(23): 9891-905.
[http://dx.doi.org/10.1007/s00253-020-10945-w] [PMID: 33052519]
[http://dx.doi.org/10.1007/s00253-020-10945-w] [PMID: 33052519]
[4]
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in world health organization regions. Gastroenterology 2018; 155(5): 1372-1382.e17.
[http://dx.doi.org/10.1053/j.gastro.2018.07.007] [PMID: 29990487]
[http://dx.doi.org/10.1053/j.gastro.2018.07.007] [PMID: 29990487]
[5]
Gladyshev N, Taame M, Kravtsov V. Clinical and laboratory importance of detecting Helicobacter pylori coccoid forms for the selection of treatment. Prz Gastroenterol 2020; 15(4): 294-300.
[http://dx.doi.org/10.5114/pg.2020.101557] [PMID: 33777268]
[http://dx.doi.org/10.5114/pg.2020.101557] [PMID: 33777268]
[6]
Kravtsov V, Mikhailova I, Grukhin Y, Rzaev D, Nosov A. High degree of gastric mucosa colonization with coccoid forms of Helicobacter reduce the efficiency of its eradication. Int J Curr Res 2016; 8(06): 32757-60.
[http://dx.doi.org/10.13140/RG.2.1.4798.4249]
[http://dx.doi.org/10.13140/RG.2.1.4798.4249]
[7]
Krzyek P, Grande R, Migda P, Paluch E, Gościniak G. Biofilm formation as a complex result of virulence and adaptive responses of Helicobacter pylori. Pathogens 2020; 9(12): 1-20.
[http://dx.doi.org/10.3390/pathogens9121062] [PMID: 33353223]
[http://dx.doi.org/10.3390/pathogens9121062] [PMID: 33353223]
[8]
Krzyek P, Grande R. Transformation of Helicobacter pylori into coccoid forms as a challenge for research determining activity of antimicrobial substances. Pathogens 2020; 9(3): E184.
[http://dx.doi.org/10.3390/pathogens9030184] [PMID: 32143312]
[http://dx.doi.org/10.3390/pathogens9030184] [PMID: 32143312]
[9]
Ramamurthy T, Ghosh A, Pazhani GP, Shinoda S. Current perspectives on viable but non-culturable (VBNC) pathogenic bacteria. Front Public Health 2014; 2: 103.
[http://dx.doi.org/10.3389/fpubh.2014.00103] [PMID: 25133139]
[http://dx.doi.org/10.3389/fpubh.2014.00103] [PMID: 25133139]
[10]
Aktas D, Bagirova M, Allahverdiyev AM, Abamor ES, Safarov T, Kocazeybek BS. Resuscitation of the Helicobacter pylori coccoid forms by resuscitation promoter factor obtained from Micrococcus luteus. Curr Microbiol 2020; 77(9): 2093-103.
[http://dx.doi.org/10.1007/s00284-020-02043-x] [PMID: 32504323]
[http://dx.doi.org/10.1007/s00284-020-02043-x] [PMID: 32504323]
[11]
Faghri J, Poursina F, Moghim S, et al. Morphological and bactericidal effects of different antibiotics on Helicobacter pylori. Jundishapur J Microbiol 2014; 7(1): e8704.
[http://dx.doi.org/10.5812/jjm.8704] [PMID: 25147656]
[http://dx.doi.org/10.5812/jjm.8704] [PMID: 25147656]
[12]
Abd-Elsalam S, Kobtan A, El-Kalla F, et al. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore) 2016; 95(24): e3879.
[http://dx.doi.org/10.1097/MD.0000000000003879] [PMID: 27310977]
[http://dx.doi.org/10.1097/MD.0000000000003879] [PMID: 27310977]
[13]
Shehata MAH, Talaat R, Soliman S, Elmesseri H, Soliman S, Abd-Elsalam S. Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection. Helicobacter 2017; 22(5): e12395.
[http://dx.doi.org/10.1111/hel.12395] [PMID: 28524341]
[http://dx.doi.org/10.1111/hel.12395] [PMID: 28524341]
[14]
Krzyek P, Migda P, Paluch E, Karwaska M, Wieliczko A, Gociniak G. Myricetin as an antivirulence compound interfering with a morphological transformation into coccoid forms and potentiating activity of antibiotics against Helicobacter pylori. Int J Mol Sci 2021; 22(5): 2695.
[http://dx.doi.org/10.3390/ijms22052695] [PMID: 33800082]
[http://dx.doi.org/10.3390/ijms22052695] [PMID: 33800082]